This oncology company engaged in the development of medicines for cancer patients has seen no estimate revision in the last 30 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s sharp climb can turn into more strength down the road.
Ariad Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider better-ranked stocks like Salix Pharmaceuticals Ltd. (SLXP), Flamel Technologies SA (FLML) and BioCryst Pharmaceuticals, Inc. (BCRX). While Salix and Flamel sport a Zacks Rank #1 (Strong Buy), BioCryst bears a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment